ArticleJournal of psychopharmacology (Oxford, England)2022
Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.
Article in Journal of psychopharmacology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Mixed-methods analysis on psychedelic-augmented meditation experiences from a randomized controlled mindfulness retreat.Scientific reports · 2026Trial
- Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use.Community mental health journal · 2026Article
- A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development.Biomolecules · 2026Review
- Psilocybin-induced neurocardiogenic syncope: a case report.Psychopharmacology · 2026Article
- Trip killers: Addressing a critical knowledge gap in psychedelic research.Journal of psychopharmacology (Oxford, England) · 2026Review
- Do undergraduates' views of psychedelics relate to the context for psychedelic use?Drug science, policy and law · 2025Article
- Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.Drug safety · 2025Article
- A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics.The Permanente journal · 2025Review
- Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use.Frontiers in psychology · 2025Article
- Aesthetic quality of psychedelic experience is linked to insight and psychological outcomes.Frontiers in psychology · 2025Article
- Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment.Journal of psychopharmacology (Oxford, England) · 2025Article
- Effects of Psychedelics in Older Adults: A Prospective Cohort Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2024Observational
- Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials.Brain sciences · 2024Review
- From chaos to kaleidoscope: Exploring factors in psychedelic self-treatment for mental health conditions.Journal of psychopharmacology (Oxford, England) · 2024Article
- Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using mixed methods.Journal of cannabis research · 2024Article
- Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon.Cancers · 2024Review
- Evidence versus expectancy: the development of psilocybin therapy.BJPsych bulletin · 2024Article
- Neuroimaging features of psilocybin-induced toxic-metabolic encephalopathy in an adolescent.BMJ case reports · 2024Article
- The development of psilocybin therapy for treatment-resistant depression: an update.BJPsych bulletin · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsilocybin-containing mushrooms are used for recreational, spiritual, self-development and therapeutic purposes. However, physiologically relatively nontoxic, adverse reactions are occasionally reported.
aimsThis study investigated the 12-month prevalence and nature of magic mushroom-related adverse reactions resulting in emergency medical treatment seeking in a global sample of people reporting magic mushroom use.
methodsWe use data from the 2017 Global Drug Survey - a large anonymous online survey on patterns of drug use conducted between November 2016 and January 2017.
resultsOut of 9233 past year magic mushroom users, 19 (0.2%) reported having sought emergency medical treatment, with a per-event risk estimate of 0.06%. Young age was the only predictor associated with higher risk of emergency medical presentations. The most common symptoms were psychological, namely anxiety/panic and paranoia/suspiciousness. Poor 'mindset', poor 'setting' and mixing substances were most reported reasons for incidents. All but one respondent returned back to normality within 24 h.
conclusionsThe results confirm psilocybin mushrooms are a relatively safe drug, with serious incidents rare and short lasting. Providing harm-reduction information likely plays a key role in preventing adverse effects. More research is needed to examine the detailed circumstances and predictors of adverse reactions including rarer physiological reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.